Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.

MLA

Guo, Cuicui, et al. “Preclinical Development of a Novel CCR8/CTLA-4 Bispecific Antibody for Cancer Treatment by Disrupting CTLA-4 Signaling on CD8 T Cells and Specifically Depleting Tumor-Resident Tregs.” Cancer Immunology, Immunotherapy, vol. 73, no. 10, Oct. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.1007/s00262-024-03794-3.

APA

Guo, C., Dai, X., Du, Y., Xiong, X., & Gui, X. (2024). Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs. Cancer Immunology, Immunotherapy, 73(10), 1–17. https://doi.org/10.1007/s00262-024-03794-3

Chicago

Guo, Cuicui, Xiaodong Dai, Yulei Du, Xiumei Xiong, and Xun Gui. 2024. “Preclinical Development of a Novel CCR8/CTLA-4 Bispecific Antibody for Cancer Treatment by Disrupting CTLA-4 Signaling on CD8 T Cells and Specifically Depleting Tumor-Resident Tregs.” Cancer Immunology, Immunotherapy 73 (10): 1–17. doi:10.1007/s00262-024-03794-3.